To confirm pharmacologically that RMC-7977-resistant tumour cells relied on YAP pathway activity, we examined the response of KPC-derived cell lines to the pan-TEAD inhibitor IAG93338, either alone or in combination with RMC-7977. The gene discussed is YAP1; the disease is neoplasm.